648.50
price up icon0.15%   1.005
 
loading
Schlusskurs vom Vortag:
$647.49
Offen:
$647.09
24-Stunden-Volumen:
37,921
Relative Volume:
0.15
Marktkapitalisierung:
$39.34B
Einnahmen:
$1.86B
Nettoeinkommen (Verlust:
$-40.29M
KGV:
-762.94
EPS:
-0.85
Netto-Cashflow:
$-1.28B
1W Leistung:
+1.42%
1M Leistung:
+0.17%
6M Leistung:
+23.40%
1J Leistung:
+62.14%
1-Tages-Spanne:
Value
$641.86
$649.91
1-Wochen-Bereich:
Value
$634.73
$649.97
52-Wochen-Spanne:
Value
$349.86
$678.21

Argen X Se Adr Stock (ARGX) Company Profile

Name
Firmenname
Argen X Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,148
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ARGX's Discussions on Twitter

Vergleichen Sie ARGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARGX
Argen X Se Adr
648.71 39.34B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
480.55 123.34B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
697.47 76.09B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.07 32.49B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
117.11 28.26B 3.30B -501.07M 1.03B -2.1146

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-17 Herabstufung Deutsche Bank Hold → Sell
2024-11-12 Hochstufung Wolfe Research Peer Perform → Outperform
2024-11-05 Hochstufung Scotiabank Sector Perform → Sector Outperform
2024-11-01 Herabstufung Robert W. Baird Outperform → Neutral
2024-11-01 Hochstufung William Blair Mkt Perform → Outperform
2024-10-10 Fortgesetzt Raymond James Strong Buy
2024-10-04 Herabstufung Deutsche Bank Buy → Hold
2024-08-06 Hochstufung Barclays Equal Weight → Overweight
2024-07-25 Hochstufung Deutsche Bank Hold → Buy
2024-07-23 Hochstufung Oppenheimer Perform → Outperform
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-20 Herabstufung Deutsche Bank Buy → Hold
2023-12-20 Herabstufung William Blair Outperform → Mkt Perform
2023-07-31 Eingeleitet Scotiabank Sector Perform
2023-07-24 Herabstufung UBS Buy → Neutral
2023-07-17 Fortgesetzt Evercore ISI Outperform
2023-06-15 Eingeleitet Societe Generale Sell
2023-05-31 Eingeleitet UBS Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-14 Hochstufung Robert W. Baird Neutral → Outperform
2022-12-07 Eingeleitet William Blair Outperform
2022-10-12 Eingeleitet Oppenheimer Perform
2022-07-29 Herabstufung Robert W. Baird Outperform → Neutral
2022-06-28 Fortgesetzt Stifel Buy
2022-05-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Hochstufung Piper Sandler Neutral → Overweight
2021-10-29 Hochstufung Guggenheim Neutral → Buy
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-10-07 Eingeleitet Jefferies Buy
2021-09-23 Hochstufung Redburn Neutral → Buy
2021-09-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-07-23 Eingeleitet Deutsche Bank Hold
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-06-18 Eingeleitet UBS Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-10 Hochstufung H.C. Wainwright Neutral → Buy
2021-04-23 Eingeleitet Redburn Neutral
2021-03-05 Bestätigt H.C. Wainwright Neutral
2021-02-02 Herabstufung Piper Sandler Overweight → Neutral
2021-01-04 Herabstufung Guggenheim Buy → Neutral
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-19 Herabstufung Evercore ISI Outperform → In-line
2020-07-29 Eingeleitet H.C. Wainwright Neutral
2020-02-10 Eingeleitet BofA/Merrill Buy
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-10-31 Hochstufung William Blair Mkt Perform → Outperform
2019-10-22 Eingeleitet JP Morgan Overweight
2019-09-27 Eingeleitet Wells Fargo Market Perform
2019-09-16 Fortgesetzt Cowen Outperform
2019-06-28 Eingeleitet Robert W. Baird Outperform
2019-01-18 Fortgesetzt SunTrust Buy
2019-01-04 Eingeleitet Morgan Stanley Overweight
2018-12-17 Eingeleitet Goldman Buy
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-06-29 Eingeleitet Nomura Buy
2018-04-09 Eingeleitet SunTrust Buy
2018-01-29 Bestätigt JMP Securities Mkt Outperform
Alle ansehen

Argen X Se Adr Aktie (ARGX) Neueste Nachrichten

pulisher
Feb 19, 2025

Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 07, 2025

BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Telecom Argentina S.A. ADR (TEO) Stock Records 32.38% Quarterly Movement - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Guru Fundamental Report for ARGXBenjamin Graham - Nasdaq

Feb 06, 2025
pulisher
Feb 03, 2025

Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.

Feb 03, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 29, 2025

argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com

Jan 29, 2025
pulisher
Jan 15, 2025

argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India

Jan 15, 2025
pulisher
Jan 14, 2025

Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com

Jan 13, 2025
pulisher
Jan 07, 2025

argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Piper Sandler increases argenx stock price target on revised estimates - Investing.com

Jan 07, 2025
pulisher
Jan 06, 2025

Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com

Jan 06, 2025
pulisher
Dec 28, 2024

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance

Dec 28, 2024
pulisher
Dec 23, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Dec 23, 2024
pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa

Dec 16, 2024
pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com

Dec 15, 2024
pulisher
Dec 12, 2024

Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN

Dec 12, 2024
pulisher
Dec 09, 2024

Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar

Dec 09, 2024
pulisher
Dec 09, 2024

Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com

Dec 09, 2024
pulisher
Dec 02, 2024

Argenx stock soars to all-time high of $620.29 - Investing.com

Dec 02, 2024
pulisher
Nov 30, 2024

10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey

Nov 30, 2024
pulisher
Nov 26, 2024

Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 26, 2024

Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India

Nov 26, 2024
pulisher
Nov 25, 2024

argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India

Nov 25, 2024
pulisher
Nov 21, 2024

Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Barclays bullish on argenx stock after positive trial results - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa

Nov 21, 2024
pulisher
Nov 20, 2024

argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com

Nov 20, 2024
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 12, 2024

Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com

Nov 12, 2024
pulisher
Nov 11, 2024

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance

Nov 11, 2024
pulisher
Nov 05, 2024

Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Nov 04, 2024
pulisher
Nov 01, 2024

Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga

Nov 01, 2024

Finanzdaten der Argen X Se Adr-Aktie (ARGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$251.40
price up icon 0.20%
$117.81
price down icon 0.21%
biotechnology ONC
$255.00
price up icon 4.37%
$23.20
price up icon 0.13%
$365.28
price down icon 0.63%
Kapitalisierung:     |  Volumen (24h):